Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 13/20 | 1.00 |
| ▸ | TYMS | P04818 | 1/20 | 0.56 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | DHFR | P00374 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10505540 | 0.88 | PNP (0.78) | PNPTYMSXDH | |
| SCHEMBL2128391 | 0.86 | PNP (0.76) | PNPTYMSXDHDHFRTLR7 | |
| SCHEMBL10506332 | 0.86 | PNP (0.76) | PNPTYMSXDHDHFR | |
| SCHEMBL10505790 | 0.86 | PNP (0.76) | PNPTYMS | |
| SCHEMBL7663884 | 0.86 | PNP (0.76) | PNPTYMSXDHKDM4EDHFR | |
| SCHEMBL9798404 | 0.86 | PNP (0.75) | PNPTYMSTLR7 | |
| Hydrochloric Acid SCHEMBL10664096 | 0.85 | PNP (0.74) | PNPTYMS | |
| SCHEMBL10507779 | 0.83 | PNP (0.71) | PNPTYMSXDHKDM4ETLR7 | |
| SCHEMBL6356585 | 0.83 | PNP (0.71) | PNPTYMSXDHKDM4ERAB9A | |
| SCHEMBL27602651 | 0.83 | PNP (0.71) | PNPTYMSXDHDHFRTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0374096-B1 | COMBINATION THERAPY INVOLVING 2',3'-DIDEOXYPURINE NUCLEOSIDE AND AN INHIBITOR OF PURINE NUCLEOSIDE PHOSPHORYLASE, AND ITS COMPOSITIONS | CIBA-GEIGY AG (CH) | 1992-12-02 | — | — | EP | claimed |
| EP-0374096-A1 | Combination therapy involving 2',3'-dideoxypurine nucleoside and an inhibitor of purine nucleoside phosphorylase, and its compositions | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | claimed |
| JP-2204414-A | — | — | None | — | — | JP | disclosed |
| US-20220211710-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH NUCLEOSIDE-METABOLISM MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-07-07 | — | — | US | disclosed |
| WO-2021022105-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH NUCLEOSIDE-METABOLISM MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-04 | — | — | WO | disclosed |
| EP-1518854-A1 | Substituted 06- benzylguanines and 7- or 9- substituted 8-aza-06-benzylguanines | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 2005-03-30 | — | — | EP | disclosed |
| US-6436945-B2 | FOR ENHANCING THE CHEMOTHERAPEUTIC TREATMENT OF TUMOR CELLS IN A MAMMAL WITH AN ANTINEOPLASTIC ALKYLATING AGENT, WHICH CAUSES CYTOTOXIC LESIONS AT THE O6-POSITION OF GUANINE; O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE (AGT) INACTIVATOR | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE OF HEALTH AND HUMAN SERVICES | 2002-08-20 | — | — | US | disclosed |
| US-6333331-B1 | USEFUL IN INACTIVATING THE HUMAN DNA REPAIR PROTEIN O.SUP.6 -ALKYLGUANINE-DNA ALKYLTRANSFERASE; ANTICANCER AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-12-25 | — | — | US | disclosed |
| EP-0550574-A1 | HETEROCYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-07-14 | — | — | EP | disclosed |
| EP-0374096-B1 | COMBINATION THERAPY INVOLVING 2',3'-DIDEOXYPURINE NUCLEOSIDE AND AN INHIBITOR OF PURINE NUCLEOSIDE PHOSPHORYLASE, AND ITS COMPOSITIONS | CIBA-GEIGY AG (CH) | 1992-12-02 | — | — | EP | disclosed |
| WO-1992005180-A1 | HETEROCYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-04-02 | — | — | WO | disclosed |
| US-4952693-A | TREATING AUTOIMMUNE DISEASES | WARNER-LAMBERT COMPANY (US) | 1990-08-28 | — | — | US | disclosed |
| JP-H02204414-A | COMBINATIONAL THERAPY USING 2',3'-DIDEOXYPURINENUCLEOSIDE/ PURINENUCLEOSIDE PHOSPHORYLASE INHIBITOR AND COMPOSITION | CIBA GEIGY AG | 1990-08-14 | — | — | JP | disclosed |
| EP-0374096-A1 | Combination therapy involving 2',3'-dideoxypurine nucleoside and an inhibitor of purine nucleoside phosphorylase, and its compositions | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | disclosed |
| US-4874862-A | Process for preparing guanine derivatives | WARNER-LAMBERT COMPANY (US) | 1989-10-17 | — | — | US | disclosed |
| EP-0156559-B1 | 8-SUBSTITUTED GUANINE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1989-08-02 | — | — | EP | disclosed |
| US-4772606-A | AUTOIMMUNE DISEASES, ORGAN TRANSPLANTS | WARNER-LAMBERT COMPANY (US) | 1988-09-20 | — | — | US | disclosed |
| US-4748177-A | Guanine derivatives | WARNER-LAMBERT COMPANY (US) | 1988-05-31 | — | — | US | disclosed |
| EP-0178178-A2 | Purine derivatives | WARNER-LAMBERT COMPANY (US) | 1986-04-16 | — | — | EP | disclosed |
| EP-0156559-A2 | 8-Substituted guanine derivatives | WARNER-LAMBERT COMPANY (US) | 1985-10-02 | — | — | EP | disclosed |